Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience

Current Medical Research and Opinion

Volumn 33, Issue 7, 2017, Pages 1337-1341

  Simons, Leon A ^a   Ortiz, Michael ^a   Freedman, Ben ^b   Waterhouse, Benjamin J ^c   Colquhoun, David ^d  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Casting Solutions Pty   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

anticoagulants; NOAC drugs; Non valvular atrial fibrillation; persistence; thromboembolic stroke

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; AUSTRALIA; COMORBIDITY; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; WARFARIN;

EID: 85019141361     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1321535     Document Type: Article

References (29)

1. Wolf PA, Abbott RD, Kannel WB., Atrial fibrillation as an independent risk factor for stroke:the Framingham Study. Stroke 1991;22:983-8
2. Hart RG, Pearce LA, Aguilar MI., Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
3. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation:a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011;106:739-49
4. Freedman B, Potpara TS, Lip GYH., Stroke prevention in atrial fibrillation. Lancet 2016;388:806-17
5. Leyden JM, Kleinig TJ, Newbury J, et al. Adelaide stroke incidence study:declining stroke rates but many preventable cardioembolic strokes. Stroke 2013;44:1226-31
6. Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605
7. Xian Y, O’Brien EC, Liang L, et al. Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation. JAMA 2017;317:1057-67
8. Salazar CA, del Aguila D, Cordova EG., Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014;3:CD009893
9. Camm AJ, Pinto FJ, Hankey GJ, et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice:barriers to and strategies for optimal implementation. Europace 2015;17:1007-17
10. Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115:31-9
11. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962
12. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials. Lancet 2014;383:955-62
13. Simons LA, Ortiz M, Freedman SB, et al. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation:recent Australian experience. Curr Med Res Opin 2016;32:1857-61
14. McHorney CA, Peterson ED, Laliberte F, et al. Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation. Clin Ther 2016;38:2477-88
15. Brown JD, Shewale AR, Talbert JC., Adherence to rivaroxaban, dabigatran and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2016;22:1319-29
16. Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9
17. Simons LA, Ortiz M, Germanos P, et al. Persistence on warfarin in patients with atrial fibrillation:experience in Australia 2006–2009. Aust Fam Physic 2013;42:659-61
18. Osterberg L, Blaschke T., Adherence to medication. N Engl J Med 2005;353:487-97
19. Abdou JK, Auyeung V, Patel JP, Arya R., Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol 2016;174:30-42
20. Pandya EY, Bajorek B., Factors affecting patients’ perception on, and adherence to, anticoagulant therapy:anticipating the role of direct oral anticoagulants. Patient 2017;10:163-85
21. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017;117:209-18
22. Forslund T, Wettermark B, Hjemdahl P., Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016;72:329-38
23. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
24. Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
25. Johnson ME, Lefèvre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation:a cohort study in UK primary care. BMJ Open 2016;6:e011471
26. Lamberts M, Staerk L, Olesen JB, et al. major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation:contemporary findings in real-life Danish patients. J Am Heart Assoc 2017;6;e004517
27. Savelieva I, Camm AJ., Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014;37:32-47
28. Vrijens B, Heidbuchel H., Non-vitamin K antagonist oral anticoagulants:considerations on once- vs twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
29. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-34